InvestorsObserver is giving Cardiff Oncology Inc (CRDF) an Analyst Rating Rank of 75, meaning CRDF is ranked higher by analysts than 75% of stocks. The average price target for CRDF is $26.666 and analyst’s rate the stock as a Strong Buy.
Wall Street analysts are rating CRDF a Strong Buy today. Find out what this means to you and get the rest of the rankings on CRDF!